Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Entacapone/Levodopa/Carbidopa Tablets (II) in Postprandial Healthy Subjects
NCT06180720Phase 1Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Dec 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of entacapone, levodopa and carbidopa in Parkinson's disease (PD) (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Peak Plasma Concentration at 10 hours, Area under the plasma concentration versus time curve from time 0 to time t at 10 hours and 1 more. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
entacaponelevodopacarbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06180720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06180720.